# ASPIRE     BIOPHARMA HOLDINGS, INC. (ASBP) · Edgar & Edgarette company card

> Aspire     Biopharma Holdings (ASBP) reported revenue of $0 million in FY2025, operating margin -312017% against a -3.8% median for pharmaceutical preparations, equity -486% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1847345 · fiscal year ended 2025-12-31 · 1 audited years read · [page](https://www.pops4.com/boards/company/ASBP) · [JSON](https://www.pops4.com/boards/company/ASBP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $6,202 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -312016.9% |
| Net margin | -394725.1% |
| Operating cash flow | −$5M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $1M |
| Long-term debt | — |
| Total assets | $1M |
| Total equity | −$6M |
| Equity ÷ assets | -485.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -199.1 (distress zone)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$4.9M in FY2025); operating loss: a margin of -312016.9% in FY2025

## Edgarette's reading

Exposure: revenue $6K (FY2025). Experience: one year on record; operating margin -312016.9%. Soundness: equity -485.9% of assets (liabilities exceed assets). Credibility: one audited year, little weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -312016.9% against a -3.8% median.

## Health Watch, last 12 months

- Item 4.01 Auditor change: 1, latest 2026-09-29 ([filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226044908/0001493152-26-044908-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-02-12 ([filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226006343/0001493152-26-006343-index.htm))

## Recent filings

- 8-K · filed 2026-09-29 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226044908/0001493152-26-044908-index.htm)
- 8-K · filed 2026-09-09 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/0001493152-26-041918-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226041725/0001493152-26-041725-index.htm)
- 8-K · filed 2026-08-19 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226039135/0001493152-26-039135-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226037819/0001493152-26-037819-index.htm)
- 8-K · filed 2026-08-10 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1847345/000149315226036777/0001493152-26-036777-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001847345.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1847345

## Cite

POPS4, Edgar & Edgarette: ASPIRE     BIOPHARMA HOLDINGS, INC. (ASBP) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/ASBP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.